Vol. 9 No. Suplemento 1 (2017)

Artigos

• Health technologies prioritization: the Brazilian case

  Denizar Araújo, Marcella Distrutti, Flávia Elias

  4-40

  • PDF (Português (Brasil))

• Cost-effectiveness analysis of obinutuzumab associated to chemotherapy for the treatment of chronic lymphocytic leukemia patients ineligible for fludarabine under the Brazilian Public Healthcare System (SUS)

  Rodrigo Shimabukuro Ho, Camila Souza, Carolina Tsuchiya, Juliana Biondo, Marcia Regina Alves

  41-48

  • PDF (Português (Brasil))

• Cost variation of antipsychotics in the public health system in Brazil: the implication for health resource use

  Denise Razzouk

  49-57

  • PDF

• The economic impact of providing dengue vaccination in the workplace in Brazil

  Laure Durand, Louise Grailles, Christophe Boissière, Sophie Beucher

  58-70

  • PDF

• Cost-effectiveness analysis of onabotulinumtoxinA in the preventive treatment of chronic migraine under the Brazilian private health care system perspective

  Elcio Piovesan, Patricia Cadecaro, Camila Pepe

  71-80

  • PDF (Português (Brasil))

• Cost-effectiveness of anti-PD-1 therapies compared with ipilimumab for the treatment of advanced melanoma under the Brazilian supplementary health system perspective

  Straus Tanaka, Guilherme Aratangy, Guareide Carelli, Lucas Fahham, Camila Pepe, Graziela Bernardino

  81-88

  • PDF (Português (Brasil))

• Cost-effectiveness analysis of pirfenidone versus nintedanib on the treatment of idiopathic pulmonary fibrosis in the perspective of the Brazilian private healthcare system

  Rodrigo Shimabukuro Ho, Camila Souza, Cintia Oliveira, Claudio Maurício Lisondo, Marcia Regina Alves

  89-95

  • PDF (Português (Brasil))

• PROCOT – Development, results and advances of the Technical Cooperation Program of the Ministry of Health for technical and economic information on medical devices

  Murilo Contó

  96-102

  • PDF (Português (Brasil))

• Healthcare expenditures and economic cycle in Brazil: a period analisys between 1980 and 2015

  Andre Medici

  103-107

  • PDF (Português (Brasil))

• The value of new medicines value based prices

  Stephen Stefani, Matheus Ferla, Juliana Scheffer

  108-110

  • PDF (Português (Brasil))

• The innovative industry in health and the media: prejudgements and challenges

  Octávio Nunes

  111-114

  • PDF (Português (Brasil))

• Efficiency frontier in health technologies assessments

  Ricardo Saad, Teresa Lemmer, Otávio Clark

  115-122

  • PDF (Português (Brasil))